Biogen
BIIB
$253.84
+5.34%
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases, with a portfolio spanning a declining multiple sclerosis franchise (40% of 2025 revenue), CD20 collaboration revenue from Roche including Rituxan, Gazyva and Ocrevus (19% of 2025 revenue), and newer growth assets such as Spinraza, Leqembi, Skyclarys, Zurzuvae and Qalsody. The company is a mid-cap neuroscience specialist rather than a broad-platform pharma, and its identity is increasingly defined by its pivot away from legacy MS dependence toward Alzheimer's, rare disease and immunology. The current investor narrative centers on whether that pivot is finally inflecting: the Q2 2026 beat and improved revenue guidance, the up-to-$1 billion RayThera immunology acquisition, and the diranersen Alzheimer's trial miss in May that showed promising secondary cognitive data but failed its primary endpoint. Bulls point to a 63.5% one-year share gain and a forward PE near 14x as evidence the market is re-rating a cheap, cash-generative turnaround, while bears flag a thin trailing net margin, a negative PEG ratio and persistent pipeline binary risk.…
BIIB
Biogen
$253.84
Related headlines
BIIB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Biogen's 12-month outlook, with a consensus price target around $247.32 and implied upside of -2.6% versus the current price.
Average Target
$247.32
0 analysts
Implied Upside
-2.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $310
Analyst target range
Coverage is deep, with 32 analysts and a consensus recommendation of "buy" (mean rating 1.83 on a 1-to-5 scale where lower is more bullish). The average target price of $243.98 implies roughly 4.9% upside from the current $232.65, a modest gap that suggests the stock has largely caught up to consensus after its 63.5% one-year run. The consensus leans bullish on rating but only mildly so on price, indicating analysts see fair value roughly where the stock trades.
The target range is wide, from a low of $175.00 (about 24.8% downside) to a high of $300.00 (about 28.9% upside), signaling meaningful disagreement about the pipeline and margin trajectory. The high target likely assumes successful commercialization of Leqembi and the immunology pipeline plus margin recovery toward historical levels, while the low target prices in continued MS erosion, margin compression and pipeline setbacks. Recent institutional actions skew constructive, with Wolfe Research upgrading to Outperform from Peer Perform on August 13, 2026, and Piper Sandler, RBC Capital, Mizuho, UBS and HC Wainwright maintaining bullish ratings, though HSBC reiterated Reduce on September 10 and Citigroup and Morgan Stanley remain Neutral/Equal Weight, so the wide spread reflects genuine two-sided debate rather than uniform conviction.
Bulls vs Bears: BIIB Investment Factors
The bull case currently has stronger evidence: a 63.54% one-year gain, an 11.5% FCF yield, a 14.08x forward PE at a 20-30% sector discount, and a Q2 2026 revenue beat with raised guidance collectively show a cheap, cash-generative business re-rating as its pivot gains traction. The bear case is real but largely about execution risk rather than balance-sheet distress, with debt-to-equity of 0.38 and a current ratio of 2.68 providing a cushion. The single most important tension is whether the declining 40%-of-revenue MS franchise can be offset by Leqembi, Skyclarys and the immunology pipeline before margin erosion (gross margin down to 56.92% in Q2 2026) becomes structural. If the new franchises inflect, the 14x forward multiple is far too cheap; if they stall, the thin 3.56% net margin validates the discount. With the stock at 96.5% of its range and only 4.9% upside to the average target, the debate is now about timing and pipeline proof rather than raw valuation.
Bullish
- Forward PE of 14.08x prices in pessimism: At $232.65, BIIB trades at 14.08x forward EPS of $20.45 versus a large-cap pharma sector that typically commands high-teens to low-twenties multiples, implying a 20-30% discount. The trailing PE of 19.89x on EPS of just $0.05 versus the forward multiple shows the market is not yet crediting the consensus profit rebound.
- Free cash flow yield near 11.5%: Trailing free cash flow of $2.969 billion against a $25.8 billion market cap produces an FCF yield of roughly 11.5%, unusually high for a company with a 70.47% trailing gross margin. That cash generation can self-fund the pipeline and the up-to-$1 billion RayThera immunology deal without straining the balance sheet.
- Massive relative strength versus market: BIIB is up 63.54% over one year versus 15.53% for SPY, a 48.01 percentage-point relative advantage, and 31.18% over six months versus 7.48% for the index. The stock sits at roughly 96.5% of its 52-week range ($138.00-$240.99), just 3.5% below the high, signaling a durable re-rating trend.
- Q2 2026 beat and guidance raise: Q2 2026 revenue of $2.736 billion rose 3.42% year over year and beat expectations, prompting management to raise revenue guidance even as it trimmed profit guidance. The July 29 report drove the stock higher, showing the market is rewarding top-line execution on the pivot away from MS.
Bearish
- Profitability is thin and volatile: Q2 2026 net income collapsed to $97.5 million on a 3.56% net margin from $319.5 million (12.89%) in Q1 2026 and $466.5 million (19.00%) in Q3 2025, and Q4 2025 posted a $48.4 million loss. Gross margin compressed to 56.92% in Q2 2026 from 73.32% in Q1 2026 and 78.23% in Q4 2025, a clear deterioration trend.
- MS franchise structurally declining: The multiple sclerosis franchise still contributed 40% of 2025 revenue, with MS product revenues of $963.3 million in the latest quarter including Tysabri at $450.8 million and Fumarate at $287.4 million. These are declining assets, so the entire growth thesis depends on Leqembi, Skyclarys and immunology offsetting a shrinking core.
- Pipeline binary risk already realized: The diranersen Alzheimer's trial missed its primary endpoint in May 2026, triggering a sharp selloff despite promising secondary cognitive data. That event demonstrates the binary nature of the pipeline, and the up-to-$1 billion RayThera deal is milestone-driven with value depending entirely on future clinical success.
- Negative PEG and distorted earnings: The PEG ratio of -0.95 reflects the mismatch between minimal trailing EPS of $0.05 and expected growth, making the trailing valuation metrics unreliable. Quarterly operating cash flow swung from $1.273 billion in Q3 2025 to $160.9 million in Q2 2025 and $448.9 million in Q2 2026, and cash fell to $1.340 billion from $3.383 billion.
BIIB Technical Analysis
Biogen is in a sustained, powerful uptrend: the stock is up 63.54% over the past year versus just 15.53% for SPY, a relative strength advantage of 48.01 percentage points. At $232.65, the shares sit at roughly 96.5% of the 52-week range (low $138.00, high $240.99), just 3.5% below the high. That positioning signals strong momentum but also meaningful overextension risk, with little overhead supply but limited margin of safety for new entries.
Short-term momentum is positive but decelerating relative to the longer-term trend. The stock gained 7.70% over the past month and 12.94% over three months, both well ahead of SPY's 1.22% and 2.69%, yet the 1-month gain is smaller than the 6-month gain of 31.18% and the 1-year gain of 63.54%, indicating the pace of advance is moderating. The most recent session fell 1.15% from $235.35 to $232.65 on volume of about 1.46 million shares, a modest pullback from the high rather than a breakdown; the 1-month relative strength of +6.48 confirms continued outperformance despite the cooling.
Key resistance sits at the 52-week high of $240.99, with a breakout above that level likely to trigger momentum-chasing flows and open blue-sky territory; support is anchored at the 52-week low of $138.00, with intermediate support likely in the $215-$220 zone where the stock consolidated in August and September. The reported beta of 0.092 is anomalously low for a biotech and should be treated with skepticism, but if accurate it implies the stock has traded with very low sensitivity to the market, meaning its 63.5% one-year move is largely idiosyncratic rather than beta-driven. The maximum drawdown of -14.34% over the period underscores that pullbacks have been sharp but contained, consistent with a high-conviction trend.
Beta
0.09
0.09x market volatility
Max Drawdown
-14.3%
Largest decline past year
52-Week Range
$138-$254
Price range past year
Annual Return
+71.8%
Cumulative gain past year
| Period | BIIB Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | -1.2% |
| 3m | +25.5% | +3.4% |
| 6m | +37.7% | +7.0% |
| 1y | +71.8% | +14.4% |
| ytd | +42.8% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BIIB Fundamental Analysis
Revenue is growing modestly rather than rapidly: Q2 2026 revenue of $2.736 billion rose 3.42% year over year, and the trailing four-quarter total of roughly $9.97 billion ($2.736B + $2.478B + $2.279B + $2.454B) shows a stable base. The multi-quarter trend is choppy, with revenue of $2.478 billion in Q1 2026, $2.279 billion in Q4 2025 and $2.454 billion in Q3 2025, implying low-single-digit growth at best. Within the segment data, MS product revenues of $963.3 million, including Tysabri at $450.8 million, Spinraza at $401.9 million and Fumarate at $287.4 million, remain the core but are structurally declining, so the investment case hinges on whether Leqembi, Skyclarys and the immunology pipeline can offset that drag.
Profitability is thin and volatile. Q2 2026 net income was just $97.5 million on a 3.56% net margin, a sharp drop from Q1 2026's $319.5 million (12.89% margin) and Q3 2025's $466.5 million (19.00% margin), and Q4 2025 posted a net loss of $48.4 million. Gross margin compressed to 56.92% in Q2 2026 from 73.32% in Q1 2026 and 78.23% in Q4 2025, while the trailing gross margin of 70.47% and operating margin of 19.14% remain respectable for large-cap pharma but are trending in the wrong direction. The Q2 cost of revenue jump to $1.179 billion and R&D of $495.6 million, plus $709.7 million in SG&A, squeezed operating income to $318.1 million (11.63% operating margin), so margin recovery depends on revenue mix and cost discipline.
Balance-sheet health is solid but cash generation is uneven. Debt-to-equity is a conservative 0.38, the current ratio is a strong 2.68, and trailing free cash flow is $2.969 billion, implying an FCF yield of roughly 11.5% on the $25.8 billion market cap, which is attractive. However, quarterly operating cash flow swung from $1.273 billion in Q3 2025 to $160.9 million in Q2 2025 and $448.9 million in Q2 2026, and cash fell to $1.340 billion at Q2 2026 from $3.383 billion, reflecting the RayThera-type deal activity and investment purchases. ROE of 7.08% and ROA of 5.21% are modest, and the $2.969 billion FCF against a $25.8 billion market cap supports the view that Biogen can self-fund its pipeline, though the volatility in quarterly cash flow warrants monitoring.
Quarterly Revenue
$2.7B
2026-06
Revenue YoY Growth
+3.4%
YoY Comparison
Gross Margin
56.9%
Latest Quarter
Free Cash Flow
$3.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BIIB Overvalued?
Because Biogen's trailing net income is positive but minimal (EPS of $0.05), the trailing PE of 19.89x is distorted and not the most informative metric; the forward PE of 14.08x is the more meaningful anchor, and the gap between trailing and forward multiples implies the market expects a substantial earnings recovery. The forward PE of 14.08x against estimated EPS of $20.45 versus trailing EPS of $0.05 reflects consensus expectations of a dramatic profit rebound, while the PS ratio of 2.63x and EV/Sales of 4.17x provide a cleaner read on the revenue-based valuation.
Against the broader drug manufacturer sector, Biogen screens cheap on most multiples: a PS of 2.63x and EV/EBITDA of 10.10x are well below the premium multiples typically commanded by large-cap pharma with comparable gross margins of 70.47%. The forward PE of 14.08x versus a sector that often trades in the high teens to low twenties implies a discount of roughly 20-30%, which is arguably justified by the declining MS franchise, thin trailing profitability and binary pipeline risk, though the 11.5% FCF yield suggests the discount may be excessive if the turnaround holds.
The historical ratio data shows Biogen's PS ratio has compressed dramatically from 15.71x in Q4 2023 and 13.69x in Q2 2024 to 2.63x currently, and its PB ratio has fallen from 2.98x in Q4 2022 to 1.41x today, placing the stock near the bottom of its own historical valuation band. That compression reflects both earnings deterioration and multiple de-rating, so the current valuation prices in considerable pessimism; if the revenue guidance raise and immunology pivot gain traction, mean reversion toward historical multiples could provide meaningful upside, whereas continued margin erosion would validate the discount.
PE
19.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin volatility and revenue concentration. Gross margin fell to 56.92% in Q2 2026 from 78.23% in Q4 2025, and net margin collapsed to 3.56% from 19.00% in Q3 2025, with Q4 2025 posting a $48.4 million loss. The MS franchise still represents 40% of 2025 revenue and is structurally declining, so earnings depend on offsetting that drag with newer assets. Quarterly operating cash flow is uneven, swinging from $1.273 billion in Q3 2025 to $160.9 million in Q2 2025 and $448.9 million in Q2 2026, while cash fell to $1.340 billion from $3.383 billion, partly reflecting deal activity like the up-to-$1 billion RayThera acquisition.
Market and competitive risks include valuation compression and pipeline binary outcomes. Although the 14.08x forward PE is a discount to sector, the stock has already rallied 63.54% in a year and sits 3.5% below its 52-week high, so any disappointment could trigger multiple compression from an extended position. The reported beta of 0.092 is anomalously low and should be treated skeptically, but if accurate it means the 63.5% move is idiosyncratic rather than market-driven, leaving the stock exposed to company-specific shocks. Competitive threats are real: AbbVie's FDA approval of its Parkinson's pill Juvmo strengthens a rival neuroscience franchise, and the diranersen primary-endpoint miss in May 2026 showed how quickly pipeline news can reverse sentiment.
In a worst-case scenario, a second major pipeline failure combined with accelerating MS erosion and continued gross-margin compression would force analysts toward the low target of $175.00, about 24.8% below the current $232.65. A deeper de-rating toward the 52-week low of $138.00 would represent roughly 40.7% downside, consistent with the stock's history of sharp drawdowns (maximum drawdown of -14.34% even within its strong uptrend). The realistic adverse path is a Q3 2026 earnings miss on margins plus a Leqembi or immunology setback, which could compress the forward multiple back toward the low end while consensus EPS estimates of $20.45 get cut, producing a compounded price decline of 25-40%.